Pure Global
NCT06248697

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors

Shanghai Cell Therapy Group Co.,Ltd·Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
αPD1/CTLA4-MSLN-CAR T cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Shanghai Cell Therapy Group Co.,Ltd
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 01, 2023
End date
Dec 31, 2026
Enrollment
16 participants
Primary outcome

Dose-limiting toxicity（DLT）

Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and
 tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T
 cells secreting PD-1 and CTLA-4 nanobodies (αPD1/CTLA-4-MSLN-CAR T cells) in patients with
 solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06248697
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06248697 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Cell Therapy Group Co.,Ltd and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.